Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 11/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 11/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NQO2 | P16083 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | NR2E3 | Q9Y5X4 | 3/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.36 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2294573 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL20709815 | 0.82 | MTNR1A (0.69) | MTNR1AMTNR1BSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2294828 | 0.79 | MTNR1A (0.65) | MTNR1AMTNR1BSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2294834 | 0.79 | MTNR1A (0.65) | MTNR1AMTNR1BSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2299352 | 0.77 | MTNR1A (1.00) | MTNR1AMTNR1BMAPT | |
| SCHEMBL2299350 | 0.77 | MTNR1A (1.00) | MTNR1AMTNR1BMAPT | |
| SCHEMBL19114476 | 0.76 | MTNR1A (0.60) | MTNR1AMTNR1BSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL12214771 | 0.75 | MTNR1A (0.59) | MTNR1AMTNR1BSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL3573426 | 0.74 | MTNR1A (0.59) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL3573423 | 0.74 | MTNR1A (0.59) | MTNR1AMTNR1BNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3400940-B1 | COMPOUNDS HAVING MELATONIN RECEPTOR AFFINITY AS PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM | TAKEDA PHARMACEUTICALS CO (JP) | 2024-08-07 | — | — | EP | claimed |
| EP-3400939-B1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AUTISM SPECTRUM DISORDER | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-16 | — | — | EP | claimed |
| US-20210130305-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AUTISM SPECTRUM DISORDER | TAKEDA PHARMACEUTICALS CO (JP) | 2021-05-06 | — | — | US | claimed |
| US-10759768-B2 | Prophylactic or therapeutic agent for autism spectrum disorder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-01 | — | — | US | claimed |
| US-20190040022-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AUTISM SPECTRUM DISORDER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-07 | — | — | US | claimed |
| US-20190008834-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-10 | — | — | US | claimed |
| EP-3400939-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AUTISM SPECTRUM DISORDER | Takeda Pharmaceutical Company Limited (JP) | 2018-11-14 | — | — | EP | claimed |
| EP-3400940-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM | Takeda Pharmaceutical Company Limited (JP) | 2018-11-14 | — | — | EP | claimed |
| EP-2029561-B1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-08-13 | — | — | EP | claimed |
| US-8552037-B2 | Tricyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-08 | — | — | US | claimed |
| US-20130079374-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-03-28 | — | — | US | claimed |
| US-20090182023-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-16 | — | — | US | claimed |
| EP-2029561-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-03-04 | — | — | EP | claimed |
| WO-2007148808-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-12-27 | — | — | WO | claimed |
| EP-3400940-B1 | COMPOUNDS HAVING MELATONIN RECEPTOR AFFINITY AS PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM | TAKEDA PHARMACEUTICALS CO (JP) | 2024-08-07 | — | — | EP | disclosed |
| CN-108697689-B | Prophylactic or therapeutic agent for autism spectrum disorder | 武田药品工业株式会社 | 2022-04-26 | — | — | CN | disclosed |
| US-20220096444-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-31 | — | — | US | disclosed |
| EP-2029561-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007148808-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007148808-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190008834-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM | MTNR1A, MTNR1B, PNMT | MTNR1A 1/4885MTNR1B 2/4885SMN1; SMN2 2157/4885 |
| US-20190040022-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AUTISM SPECTRUM DISORDER | MTNR1A, MTNR1B, MCHR1 | MTNR1A 1/4885MTNR1B 2/4885SMN1; SMN2 1496/4885 |
| US-20220096444-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM | MTNR1A, MTNR1B, PNMT | MTNR1A 1/4885MTNR1B 2/4885SMN1; SMN2 2157/4885 |
| US-20090182023-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, CYP11B2 | MTNR1A 1/4885MTNR1B 2/4885SMN1; SMN2 3507/4885 |
| US-20210130305-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AUTISM SPECTRUM DISORDER | MTNR1A, MTNR1B, MCHR1 | MTNR1A 1/4885MTNR1B 2/4885SMN1; SMN2 1496/4885 |
| US-10759768-B2 | Prophylactic or therapeutic agent for autism spectrum disorder | MTNR1A, MTNR1B, MCHR1 | MTNR1A 1/4885MTNR1B 2/4885SMN1; SMN2 1496/4885 |
| US-20130079374-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, CYP11B2 | MTNR1A 1/4885MTNR1B 2/4885SMN1; SMN2 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.